Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1819133 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $27.57Day +6.65%Mkt cap $4.0B1Y +337.6%Off 52W high −19.8%Vol (1Y) 101.2%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,241 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest29.5% of sh out |
| Days to cover15.3d |
| 13F net flow (QoQ)+1.24% |
| Top-10 13F concentration53.6% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$57.0M |
| Earnings (TTM)-$107.2M |
| ROE−37.2% |
| Net margin−162.9% |
| ROIC−48.3% |
| Sales growth 3Y35.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+211.2% |
| 1Y+337.6% |
| 3Y+715.7% |
| Since incept. (ann.)+23.8% |
Total return through 2026-07-30 · series begins 2021-08-12. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)101.2% |
| Ann. volatility (3Y)116.0% |
| Sharpe (1Y)1.92 |
| Sharpe (3Y)1.11 |
| Max drawdown (1Y)−29.2% |
| Max drawdown (3Y)−91.5% |
| Beta (3Y vs SPY)−0.29 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 13.3M | $278M | 9.32% | +791.9% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 12.8M | $268M | 8.98% | +20.8% |
| Boxer Capital Management, LLC | 10.9M | $228M | 7.62% | +0.0% |
| TCG Crossover Management, LLC | 10.5M | $220M | 7.38% | −17.5% |
| FMR LLC | 9.9M | $207M | 6.94% | +245.4% |
| FARALLON CAPITAL MANAGEMENT LLC | 9.1M | $190M | 6.38% | −30.3% |
| BlackRock, Inc. | 8.7M | $183M | 6.13% | +2.4% |
| Woodline Partners LP | 8.0M | $167M | 5.61% | −20.6% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 126.7% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 38,250,843 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$0.32 | — | $0 | −100.0% |
| 2025-12-31 | 2026-03-05 | — | — | $0 | −100.0% |
| 2025-09-30 | 2025-11-04 | $0.13 | — | $53.8M | +363.6% |
| 2025-06-30 | 2025-08-05 | −$0.35 | — | $3.2M | −84.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Collaboration Revenue 100%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
